Researchers led by Nobel Laureate David Baker have developed novel AI-based methods to design protein binders targeting intrinsically disordered regions (IDRs), traditionally considered undruggable due to their flexible, dynamic nature. These AI approaches rely on amino acid sequences without requiring structural data, facilitating drug discovery against IDRs implicated in pain, cancer, and neurological diseases. Successful design against targets like dynorphin, BRCA1 variants, and amylin positions this work as a breakthrough in accessing a vast, previously elusive class of therapeutic targets.